Core Insights - Can-Fite BioPharma's CF602 targets erectile dysfunction (ED) in diabetic patients and non-responders to existing medications, addressing a significant unmet need in a $3.2 billion market [1][2][3] Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [1][5] - The company has received a Notice of Allowance for its patent application in Brazil, expanding intellectual property protection for CF602 beyond the U.S. and Europe [2] Market Context - The current ED market is valued at $3.2 billion, with standard treatments like Viagra and Cialis effective for approximately 65%-70% of patients [2] - An estimated 30%-35% of ED patients are non-responders to these treatments, and around 16 million men with diabetes are contraindicated from using them [2] Product Details - CF602 is an A3 adenosine receptor (A3AR) allosteric modulator that enhances receptor activity and avoids desensitization, potentially offering a new treatment option for ED [4] - Preclinical studies indicate that CF602 can improve erectile function and vascular health in diabetic models, showing promise for restoring muscle collagen and endothelial function [3][4] Clinical Development - Can-Fite's lead drug candidate, Piclidenoson, is in Phase III trials for psoriasis, while Namodenoson is being evaluated for hepatocellular carcinoma and other cancers [5] - CF602 is positioned as a third drug candidate with demonstrated efficacy in treating erectile dysfunction [5]

Core Viewpoint - The article discusses the disruption of established pharmaceutical monopolies, particularly focusing on the case of Viagra and the emergence of cost-effective alternatives in the Chinese market, highlighting the impact of competitive pricing and innovative business models on traditional market leaders [1][10]. Section Summaries Introduction - The launch of deepseek, a large model trained with 2048 NVIDIA H800 chips, parallels historical market disruptions, leading to significant declines in stock prices for major players like NVIDIA, suggesting a pattern of vulnerability in perceived monopolies [1]. Origin of Viagra - Viagra, developed from an unexpected discovery in the 1990s, became a commercial success with over $32 billion in sales from 1998 to 2017, establishing a strong market presence during its patent period [2][3]. Challenges to Viagra - Despite the introduction of Cialis in 2002, Viagra maintained its dominance due to similar pricing strategies among leading pharmaceutical companies, which avoided triggering price wars [5][6]. Emergence of Chinese Competitors - Following the expiration of Viagra's patent in China in 2014, local companies introduced generics at 20%-30% lower prices, leading to a significant market shift with products like "惯爱" priced at 3-6 RMB, drastically reducing patient costs [6][7]. Business Strategy of "惯爱" - The success of "惯爱" is attributed to a disruptive pricing strategy that expands market share and reduces costs through economies of scale, creating a positive feedback loop of growth and innovation [7][8]. Production and Supply Chain Advantages - China's position as the largest producer of active pharmaceutical ingredients has lowered production costs, enabling competitive pricing for domestic drugs [8][9]. Technological Advancements in Production - The automation and digitization of production processes in China have enhanced efficiency, allowing companies like "惯爱" to maintain high-quality standards while keeping prices low [9]. Reconstructing Market Dynamics - The integration of online healthcare services with pharmaceutical distribution has transformed the erectile dysfunction drug market, shifting the focus from price competition to a comprehensive service model [10].

As filed with the Securities and Exchange Commission on February 21, 2023 Registration No. 333-269240 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Texas 8099 87-3841292 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numb ...

As filed with the Securities and Exchange Commission on January 26, 2023 Registration No. 333-269240 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Texas 8099 87-3841292 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numbe ...

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 As filed with the Securities and Exchange Commission on January 13, 2023 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Texas 8099 87-3841292 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15110 N. Dallas Parkwa ...